Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This letter confirms that despite initial regrowth, a high recurrence rate of alopecia remains common, and only 28% of patients with alternate-day prednisone therapy saw lasting improvements.

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

This study found that alopecia areata patients in Central Europe with comorbid chronic inflammatory disorders, especially atopic dermatitis, bronchial asthma, or Hashimoto's thyroiditis, had an increased likelihood of experiencing early-onset, severe, or prolonged disease compared to those without such comorbidities.

This study is the first to document significant age-related pathologies in endangered captive Julia Creek dunnarts, highlighting hormonal dysregulation and reproductive issues in females, while males exhibited higher occurrences of cutaneous diseases and testicular degeneration, providing valuable insight for conservation efforts.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

In this study, researchers found that the management of alopecia areata in Poland is inadequate, despite following international guidelines, due to limited access to advanced treatments and insufficient use of severity assessments and psychosocial support.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This abstract presents a case of arsenical dermatitis with pigmentation and alopecia developed during treatment with arsphenamine for a positive Wassermann reaction.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

In this retrospective study of 123 pediatric alopecia areata patients, hair loss episodes were most frequent in winter and showed significant correlations with air pressure and hours of sunlight, especially in non-atopic individuals, suggesting a role for climate factors in seasonal hair loss patterns.

In this case report from Cipto Mangunkusumo Hospital Jakarta, alopecia areata was identified as the most common type of baldness in the facility's skin and genital polyclinics from 2009 to 2011, representing 39.7% of cases.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.

Fumaric acid esters might help treat alopecia areata, but more research is needed.

This study concluded that exclamation mark hairs are the most reliable marker of disease activity in alopecia areata, with broken hairs, triangular hairs, and black dots also increasing the probability of active disease.

This source describes the American Board of Hair Restoration Surgery's mission to set standards and evaluate skills in hair restoration surgery, but does not report any specific study results.

This study reported significant challenges in the UK care system for alopecia areata patients, including inconsistent care pathways, long waiting times, inadequate access to specialists, and insufficient resources, particularly affecting referral processes and treatment access.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

In this study, NH Asian alopecia areata patients reported the highest levels of severe disease, with NH White patients having the most eyebrow involvement and Hispanic patients showing the least severity.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.